IperionX (NASDAQ:IPX) Sets New 52-Week Low - Should You Sell?

Key Points

• IperionX shares fell to a new 52-week low of $13.14, trading well below their 50-day average of $19.18 and 200-day average of $26.73.
• Analyst sentiment remains mostly positive but mixed: six analysts rate the stock a Buy versus one Sell, producing a “Moderate Buy” consensus and an average price target of $42, while some targets have been lowered.
• The company reported a quarterly loss of $0.50 per share, though its balance sheet shows low leverage and solid liquidity, with a 0.04 debt-to-equity ratio and a 3.24 current ratio.

IperionX Limited Sponsored ADR (NASDAQ:IPX - Get Free Report)'s share price hit a new 52-week low during mid-day trading on Wednesday. The stock traded as low as $13.14 and last traded at $13.34, with a volume of 210,253 shares. The stock had previously closed at $13.89.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Roth Capital set a $53.00 target price on shares of IperionX in a research report on Wednesday, August 5th. B. Riley Financial reduced their price target on shares of IperionX from $52.00 to $34.00 and set a "buy" rating for the company in a report on Wednesday, September 30th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of IperionX in a research report on Thursday, October 15th. Finally, Jefferies Financial Group assumed coverage on shares of IperionX in a research note on Wednesday, September 2nd. They set a "buy" rating and a $26.00 price objective on the stock. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, IperionX has a consensus rating of "Moderate Buy" and a consensus price target of $42.00.

IperionX Price Performance

The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.95 and a current ratio of 3.24. The business has a 50 day moving average of $19.18 and a two-hundred day moving average of $26.73.

IperionX (NASDAQ:IPX - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($0.50) earnings per share for the quarter. As a group, equities analysts forecast that IperionX Limited Sponsored ADR will post -0.13 EPS for the current fiscal year.

Institutional Trading of IperionX

Several hedge funds have recently modified their holdings of IPX. Private Advisor Group LLC grew its position in shares of IperionX by 69.9% in the 1st quarter. Private Advisor Group LLC now owns 63,111 shares of the company's stock worth $1,643,000 after buying an additional 25,964 shares during the last quarter. Connective Capital Management LLC purchased a new stake in IperionX during the second quarter valued at approximately $160,000. GAMMA Investing LLC lifted its position in IperionX by 40.3% during the second quarter. GAMMA Investing LLC now owns 1,681 shares of the company's stock valued at $50,000 after acquiring an additional 483 shares during the last quarter. Finally, DLD Asset Management LP purchased a new stake in IperionX during the first quarter valued at approximately $260,000. 2.76% of the stock is owned by hedge funds and other institutional investors.

About IperionX

IperionX Limited NASDAQ: IPX is a materials technology company focused on developing a U.S.-based, lower-carbon titanium supply chain. The company is working to produce titanium metal, powder and other titanium products for aerospace, defense, automotive, medical and other advanced manufacturing applications.

IperionX is developing its Titan Project in Tennessee, which is designed to supply titanium minerals and support domestic production of titanium products. The project is intended to integrate the processing of titanium mineral resources with downstream manufacturing, reducing reliance on overseas sources of titanium.

The company is also advancing proprietary processing technologies, including its Hydrogen Assisted Metallothermic Reduction process, which is designed to produce titanium metal and powder with lower energy requirements than conventional methods.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.